Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Kala Pharmaceuticals Inc (NQ: KALA)
4.970 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 5:01 PM EST, Dec 18, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 4.970
Bid (Size) 4.810 (1)
Ask (Size) 5.220 (1)
Prev. Close 4.970
Today's Range 4.970 - 4.970
52wk Range 4.920 - 20.17
Shares Outstanding 24,562,400
Dividend Yield N/A
Performance
YTD
-73.81%
-73.81%
1 Month
-20.73%
-20.73%
3 Month
-53.64%
-53.64%
6 Month
-62.77%
-62.77%
1 Year
-71.58%
-71.58%
Top News
More News
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in... Read More
from Business Wire News Releases
New Research Coverage Highlights Vmware, Kala Pharmaceuticals, El Pollo Loco, Integer, AAC, and Vectren — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Vmware, Inc. (NYSE:VMW),... Read More
from GlobeNewswire News Releases
More News
Read More
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results
from Business Wire News Releases
Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
from Business Wire News Releases
Component Price Targets Imply 27% Gains Ahead For Russell 2000
category ETFs
from ETF Channel
RSI Alert: Kala Pharmaceuticals Now Oversold
category Stocks
from Market News Video
Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs
from Business Wire News Releases
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
from Business Wire News Releases
Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO
from Business Wire News Releases
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease
from Business Wire News Releases
Sum Up The Parts: Russell 2000 Has 18% Upside
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.